The number of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic is rising in North Carolina, just as it is ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...